News
Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...
4d
News-Medical.Net on MSNSemaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial showsA phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...
Adverse reactions to weight-loss jabs are set to soar by more than 350% in a single year, according to the latest data.
Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.
CEO Erez Israeli has projected double-digit growth for FY26, primarily on the back of semaglutide launches and pipeline ...
2d
Verywell Health on MSNWegovy vs. Ozempic: Which Is the Better Weight Loss Drug?Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.
HealthDay News — For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study ...
A novel investigational endoscopic procedure targeting the duodenum appears beneficial in improving glycemic parameters in ...
The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results